原发性肺黏液腺癌的研究进展

doi:10.11904/j.issn.1002-3070.2017.05.015

摘要/Abstract

摘要： 原发性肺黏液腺癌多发生于成年男性,是发病率低的肺腺癌的一种亚型,因其无明显临床特异性,容易造成误诊,给患者造成不良的预后,因此我们需要进一步了解该种疾病并通过多种手段早期确诊。手术治疗仍然是该病的首选方式,不仅可以切除病灶还可以进一步病理确诊、基因检测、肿瘤分期及预后判定,以及为后续化疗做准备。最近几年,随着基因技术的不断发展与创新,发现该疾病的发生与KRAS基因突变、ALK基因重排以及其相关信号通路有关。相关基因突变和信号通路可成为治疗该病的靶点,这为新的靶向药物的研制提供了多种思路。但是仍然有许多问题需要进一步研究,包括原发性肺黏液腺癌的标准化疗方案、靶向药物的耐药问题以及新的KRAS抑制剂的研制。本文从原发性肺黏液腺癌的定义和发病机制、诊断以及最新的一些治疗手段研究进行综述。

关键词: 原发性肺黏液腺癌, EGFR, ALK, KRAS, 靶向治疗

Abstract: Primary pulmonary mucinous adenocarcinoma with a low incidence,a subtype of lung adenocarcinoma,occurs in adult males because of its no significant clinical specificity,likely to cause misdiagnosis,and patients with adverse prognosis.Thus,we need further to understand this disease and early diagnosis through a variety of methods as soon as possible.Surgical treatment is still the preferred mode of this disease.With addition to resecting lesions,it is also further pathological diagnosis,gene testing,tumor staging and prognosis as well as preparation for following-up chemotherapy.In recent years,with the continuous development of genetic technology and innovation,the occurrence of this disease has been found to be related to KRAS gene mutation,ALK gene rearrangement and its related signal pathway.Related gene mutations and signaling pathways can serve as a target for the treatment of this disease,which provides a variety of ideas for the development of new targeted drugs.However,there are still many problems that need further study,including standard chemotherapy for primary pulmonary mucinous adenocarcinoma,drug resistance to targeted drugs,and the development of new KRAS inhibitors.This article reviews the definition of primary pulmonary mucinous adenocarcinoma and pathogenesis,diagnosis and some of the latest treatment Methods .

Key words: Primary pulmonary mucinous adenocarcinoma, EGFR, ALK, KRAS, Target therapy

中图分类号:

R734.2

黄承路, 韩少辉徐苏琴综述, 赵俊刚审校. 原发性肺黏液腺癌的研究进展[J]. 实用肿瘤学杂志, 2017, 31(5): 463-467.

HUANG Chenglu, HAN Shaohui, XU Suqin, ZHAO Jungang. The research progress of primary pulmonary mucinous adenocarcinoma[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 463-467.

参考文献

1 Kish JK,Ro JY,Ayala AG,et al.Primary mucinous adenocarcinoma of the lung with signet-ring cells:a histochemical comparison with signet-ring cell carcinomas of other sites[J].Hum Pathol,1989,20(11):1097-1102.
2 Travis WD,Brambila E,Muller-Hermelink GK,et al.World Health Organization classification of tumours,pathology and genetics of tumours of the lung,pleura,thymus and heart[M].Lyon:IARC Press,2004:9-124.
3 Travis WD,Brambilla E,Noguchi M,et al.International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma[J].J Thorac Oncol,2011,6(2):244-285.
4 Travis WD,Brambilla E,Nicholson AG,et al.The 2015 world health organization classification of lung tumors:impact of genetic,clinical and radiologic advances since the 2004 classification[J].J Thorac Oncol,2015,10(9):1243-1260.
5 Kim J,Jang SJ,Choi CM,et al.Correlation of histologic subtypes and molecular alterations in pulmonary adenocarcinoma:therapeutic and prognostic implications[J].Adv Anat Pathol,2016,23(5):330-338.
6 Kadota K,Yeh YC,D'Angelo SP,et al.Associations between mutations and histologic patterns of mucin in lung adenocarcinoma:invasive mucinous pattern and extracellular mucin are associated with KRAS mutation[J].Am J Surg Pathol,2014,38(8):1118-1127.
7 Maeda Y,Tsuchiya T,Hao H,et al.Kras(G12D)and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung[J].J Clin Invest,2012,122(12):4388-4400.
8 Hwang DH,Sholl LM,Rojas-Rudilla V,et al.KRAS and NKX2-1 mutations in invasive mucinous adenocarcinoma of the lung[J].J Thorac Oncol,2016,11(4):496-503.
9 Shim HS,Kenudson M,Zheng Z,et al.Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung[J].J Thorac Oncol,2015,10(8):1156-1162.
10 Guo M,Tomoshige K,Meister M,et al.Gene signature driving invasive mucinous adenocarcinoma of the lung[J].EMBO Mol Med,2017,9(4):462-481.
11 Qu Y,Che N,Zhao D,et al.The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma[J].Tumour Biol,2015,36(8):6417-6424.
12 Hata A,Katakami N,Fujita S,et al.Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma[J].J Thorac Oncol,2010,5(8):1197-1200.
13 Wang J,Dong Y,Cai Y,et al.Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status[J].J Cancer Res Clin Oncol,2014,140(3):453-460.
14 英天舒,张晓晔.31例原发性肺黏液腺癌的CT表现与病理特点分析[J].实用癌症杂志,2016,31(4):567-568.
15 Ichinokawa H,Ishii G,Nagai K,et al.Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation[J].Hum Pathol,2013,44(12):2636-2642.
16 Wang Z,Wang EH,Liu DG.Pathological diagnosis and differential diagnosis for primary pulmonary mucinous epithelial tumors[J].Zhonghua Zhong Liu Za Zhi,2017,39(1):1-6.
17 张洁,陈昶,郑卉,等.57例原发性肺黏液腺癌的临床分析[J].中华肿瘤杂志,2009,31(1):66-68.
18 Zhang Y,Li J,Wang R,et al.The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma[J].Sci Rep,2014,4:7163.
19 Meng D,Yuan M,Li X,et al.Prognostic value of K-RAS mutations in patients with non-small cell lung cancer:a systematic review with meta-analysis[J].Lung Cancer,2013,81(1):1-10.
20 Ostrem JM,Peters U,Sos ML,et al.K-Ras(G12C)inhibitors allosterically control GTP affinity and effector interactions[J].Nature,2013,503(7477):548-551.
21 Dogan Turacli I,Ozkan AC,Ekmekci A.The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines[J].Tumour Biol,2015,36(12):9339-9345.
22 Naidoo J,Drilon A.KRAS-Mutant lung cancers in the era of targeted therapy[J].Adv Exp Med Biol,2016,893:155-178.
23 Ku BM,Jho EH,Bae YH,et al.BYL719,a selective inhibitor of phosphoinositide 3-Kinase α,enhances the effect of selumetinib(AZD6244,ARRY-142886)in KRAS-mutant non-small cell lung cancer[J].Invest New Drugs,2015,33(1):12-21.
24 Hurbin A,Wislez M,Busser B,et al.Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma[J].J Pathol,2011,225(1):83-95.
25 Wislez M,Antoine M,Baudrin L,et al.Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib[J].Lung Cancer,2010,68(2):185-191.
26 Nakaoku T,Tsuta K,Ichikawa H,et al.Druggable oncogene fusions in invasive mucinous lung adenocarcinoma[J].Clin Cancer Res,2014,20(12):3087-3093.
27 Duruisseaux M,McLeer-Florin A,Antoine M,et al.NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma[J].Cancer Med,2016,5(12):3579-3585.
28 Shin DH,Lee D,Hong DW,et al.Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung[J].Oncotarget,2016,7(43):69450-69465.
29 Yoshida A,Tsuta K,Nakamura H,et al.Comprehensive histologic analysis of ALK-rearranged lung carcinomas[J].Am J Surg Pathol,2011,35(8):1226-1234.
30 Fu S,Wang F,Shao Q,et al.Detection of EML4-ALK fusion gene in Chinese non-small cell lung cancer by using a sensitive quantitative real-time reverse transcriptase PCR technique[J].Appl Immunohistochem Mol Morphol,2015,23(4):245-254.
31 Yoshida A,Tsuta K,Watanabe S,et al.Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component[J].Lung Cancer,2011,72(3):309-315.
32 Popat S,Gonzalez D,Min T,et al.ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma[J].Lung Cancer,2012,75(3):300-305.

[1]	朱琳,张春霞. 纳米载药系统靶向肿瘤干细胞的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 276-279.
[2]	李悦, 徐可, 韩增祥, 孙敏, 樊国华综述, 张勇审校. 结肠癌中肿瘤相关巨噬细胞的作用及靶向治疗的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 450-454.
[3]	王元综述, 孙轶华审校. β-连环蛋白在软组织肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 455-459.
[4]	张婷, 贾迪(综述), 杨丹(审校). 骨肉瘤的生物学治疗进展[J]. 实用肿瘤学杂志, 2018, 32(3): 254-257.
[5]	黄倩倩, 马建加, 吴强, 刘彬彬, 沐晓芹, 刘树林审校. 肿瘤干细胞及肿瘤靶向治疗的研究进展[J]. 实用肿瘤学杂志, 2017, 31(6): 533-537.
[6]	孙禹琪,陈秀玮. CTGF/CCN2在恶性肿瘤的发生发展及靶向治疗中的研究进展[J]. 实用肿瘤学杂志, 2017, 31(4): 363-366.
[7]	曲媛媛，徐向英，庄明，殷洪涛，胡松柳，王春波，曹阳. 尼妥珠单抗对肺癌A549细胞系的体外放射增敏效应[J]. 实用肿瘤学杂志, 2016, 30(6): 497-501.
[8]	左志超, 苏丹柯, 邓文娟综述, 金观桥审校. ELAM-1在肿瘤靶向治疗中的应用进展[J]. 实用肿瘤学杂志, 2016, 30(5): 444-447.
[9]	赵相轩, 温锋, 毛晓楠综述, 卢再鸣审校. 细胞凋亡在原发性肝癌治疗中的作用研究进展[J]. 实用肿瘤学杂志, 2016, 30(5): 448-452.
[10]	赵相轩,温锋综述,卢再鸣审校. 细胞凋亡在胰腺癌治疗中的作用[J]. 实用肿瘤学杂志, 2016, 30(4): 375-379.
[11]	刘伟综述, 李惠艳审校. 表皮生长因子受体与放射敏感性关系的研究进展[J]. 实用肿瘤学杂志, 2016, 30(3): 275-278.
[12]	潘夏综述, 江建平审校. Alectinib在非小细胞肺癌治疗中的研究进展[J]. 实用肿瘤学杂志, 2016, 30(1): 75-79.
[13]	吕福莲, 高翔综述, 金艾顺审校. 肿瘤干细胞潜在标志物DCLK1在消化道恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2015, 29(5): 458-461.
[14]	张佳文, 曹京燕, 金时综述, 于雁审校. Hsp90抑制剂NVP-AUY922单药及联合用药在肿瘤治疗中的研究进展[J]. 实用肿瘤学杂志, 2015, 29(3): 284-288.
[15]	刘恩瑞,任欢,赵宇(综述),苏君(审校). 胶质母细胞瘤经典亚型特征性基因变异的研究进展[J]. 实用肿瘤学杂志, 2015, 29(2): 136-139.